Literature DB >> 27264548

An Investigation into the Scale and Impact of Self-Reported Foot Problems Associated with Systemic Lupus Erythematosus: A Study Protocol and Survey Questionnaire Development.

Anita Ellen Williams1, Lindsey Cherry2, Alison Blake3, Begonya Alcacer-Pitarch4, Christopher Edwards2, Neil Hopkinson5, Edward Vital4, Lee-Suan Teh6.   

Abstract

BACKGROUND: Systemic lupus erythematosus (SLE) can manifest with arthralgia and myalgia, and, in severe cases, disorganization of the joints and tendon rupture. Further, Raynaud's phenomenon and other circulatory problems such as vasculitis have been reported, and may be associated with loss of sensation and ulcers. Associated with impaired peripheral neurovascular function there is the potential for changes in tissue viability leading to thinning of the skin or callus formation. In addition, resistance to infections may be reduced, such as fungal infection of the skin and nails, bacterial infection associated with wounds and viral infections such as verruca. There is a dearth of evidence for the effects of SLE in the foot, the prevalence of foot problems in SLE and the impact of these on the individual. In addition, it is not known if people with SLE and foot problems have access to specialist care through foot health services. Hence, there is a need to investigate the scale of foot problems associated with SLE. In order to achieve this, a questionnaire needs to be developed in order to carry out a national survey in England.
METHODS: The items required for the questionnaire were generated using a focus group, which comprised patient advisers with SLE, consultants who specialized in SLE, specialist rheumatology podiatrists and specialist rheumatology nurses. From this consensus approach to the item generation, the draft questionnaire was developed with agreement on themes, question format and overall structure. Additionally, the Manchester Pain and Disability Questionnaire was included in order to capture levels of pain and associated disability. An iterative process followed, with feedback from the focus group reducing the number of other items from 53, until the penultimate version of questionnaire was produced with 50 items. Following on from this, a process of cognitive debriefing was used with two people with SLE who were naïve to the questionnaire. Minor changes to two questions and the layout was required before a final version of the questionnaire was produced. DISCUSSION: The questionnaire will be used for a study which aims to identify the frequency of patients' self-reported foot problems, the impact of foot problems on their lives and the status of foot care provision. This will be achieved through a survey of people with SLE across six clinical sites and interviews with some people in order to explore their experience of foot problems. The results from the present study will provide the information required to inform further research. In addition, it could potentially inform the design and delivery of foot health information and services to this patient group.
Copyright © 2015 John Wiley & Sons, Ltd. Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Systemic lupus erythematosus; foot; interviews; podiatry; questionnaire

Mesh:

Year:  2015        PMID: 27264548     DOI: 10.1002/msc.1119

Source DB:  PubMed          Journal:  Musculoskeletal Care        ISSN: 1478-2189


  2 in total

1.  Work participation, mobility and foot symptoms in people with systemic lupus erythematosus: findings of a UK national survey.

Authors:  M J Stevens; K Walker-Bone; D J Culliford; B Alcacer-Pitarch; A Blake; N Hopkinson; L S Teh; E M Vital; C J Edwards; A E Williams; L Cherry
Journal:  J Foot Ankle Res       Date:  2019-04-29       Impact factor: 3.050

Review 2.  A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus.

Authors:  Thomas Dörner; Edward M Vital; Sarah Ohrndorf; Rieke Alten; Natalia Bello; Ewa Haladyj; Gerd Burmester
Journal:  Rheumatol Ther       Date:  2022-03-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.